← 홈

Antibody · 혈액암 (AML/ALL)

286개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 286개
AntibodystaleRochePhase 2

Targeted therapy with bevacizumab (Targeted therapy with bevacizumab)

Locally Advanced Rectal Cancer (LARC) · Locally Advanced Rectal Cancer (LARC)

#LocallyAdvancedRectalCancerLARC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleBeiGenePhase 2

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Non-squamous Non-small Cell Lung Cancer; EGFR Gene Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleJunshi BiosciencesPhase 2

Toripalimab+cetuximab (Toripalimab+cetuximab)

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma · Patients With Locally Recurrent Resectab

#PatientsWithLocallyRecurrentRese#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

pembrolizumab (Keytruda, Capecitabine Tablets + Oxaliplatin, Trastuzumab + Pembrolizumab + CAPOX, Trastuzumab + Pembrolizumab + CAPOX( Capecitabine Tablets + Oxaliplatin) or FP (Fluorouracil Injection+Cisplatin))

Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma · Patients With Unresectable Locally Advan

#PatientsWithUnresectableLocallyA#Antibody#Phase3#항체#면역항체+2
효능 ORR 80%임상시험 1상태 RECRUITING
AntibodystaleCentre Hospitalier Universitair…Phase 2

nivolumab (Opdivo, UCPVax + Nivolumab)

Advanced Non-small Cell Lung Cancer · Advanced Non-small Cell Lung Cancer

#AdvancedNon-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleTJ Biopharma Co., Ltd.Phase 3

Uliledlimab (Uliledlimab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleMersana TherapeuticsPhase 3

Upifitimab rilsodotin (Upifitimab rilsodotin)

High Grade Serous Ovarian Cancer; Fallopian Tube Cancer · High Grade Serous Ovarian Cancer

#HighGradeSerousOvarianCancer#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleBeijing Biostar Pharmaceuticals…Phase 2

Utidelone combined with Bevacizumab (Utidelone combined with Bevacizumab)

Non-small Cell Lung Cancer Patients with Brain Metastases · Non-small Cell Lung Cancer Patients with

#Non-smallCellLungCancerPatientsw#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleNational Cancer Institute (NCI)Phase 2

Varlilumab (Varlilumab)

Metastatic Distal Bile Duct Adenocarcinoma; Metastatic Gallbladder Carcinoma · Metastatic Distal Bile Duct Adenocarcino

#MetastaticDistalBileDuctAdenocar#Antibody#Phase2#항체#면역항체+3
효능 ORR 7%임상시험 1상태 RECRUITING
AntibodystaleCatalYm GmbHPhase 2

Visugromab (Visugromab)

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleCatalYm GmbHPhase 2

recommended dose for expansion (Visugromab RDE, Visugromab RDE (recommended dose for expansion))

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#항체#면역항체+3
효능 ORR 100%임상시험 1상태 RECRUITING
AntibodystaleXencor, Inc.Phase 2

Vudalimab + Carboplatin + Pemetrexed (Vudalimab + Carboplatin + Pemetrexed)

Nonsquamous Non-small Cell Lung Cancer · Nonsquamous Non-small Cell Lung Cancer

#NonsquamousNon-smallCellLungCanc#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleXencor, Inc.Phase 2

pembrolizumab (Keytruda, XmAb18087 ± Pembrolizumab)

Merkel Cell Carcinoma; Small Cell Lung Cancer · Merkel Cell Carcinoma

#MerkelCellCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleInstitute of Hematology & Blood…Phase 2

Zanubrutinib, Fludarabine, cyclophosphamide and rituximab (Zanubrutinib, Fludarabine, cyclophosphamide and rituximab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleInstitute of Hematology & Blood…Phase 2

Zanubrutinib, bendamustine, rituximab (Zanubrutinib, bendamustine, rituximab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleGilead SciencesPhase 2

ZIM (Zimberelimab, Zimberelimab (ZIM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleJiangsu Cancer Institute & Hosp…Phase 2

QL1706 (apalolimab and toripalimab, apalolimab and toripalimab (QL1706))

NSCLC; NSCLC (Non-small Cell Lung Cancer) · NSCLC

#NSCLC#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleNational Cancer Institute (NCI)Phase 2

apolizumab (apolizumab)

Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, atezolizumab / tiragolumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePreclinical

bevacizumab plus nab-paclitaxel and platinum (bevacizumab plus nab-paclitaxel and platinum)

Non-small Cell Lung Cancer Metastatic · Non-small Cell Lung Cancer Metastatic

#Non-smallCellLungCancerMetastati#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING

13 / 15 페이지

← 이전다음 →